However, as the drug exposure was short-term, further study is needed to address if prolonged use of mutant specific IDH2 inhibitor can induce anti-tumor effects in IDH2 mutant high-grade astrocytoma. The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).